Agenus Inc. announces the closing of a strategic collaboration with Zydus Lifesciences Ltd.
The collaboration aims to accelerate global development and potential commercialization of Agenus' BOT+BAL immunotherapy combination program.
Agenus grants Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with royalties on net sales in those territories.
Financial Terms
Upfront Consideration: $75 million cash payment, Equity Investment: $16 million purchase by Zydus of Agenus common stock, Contingent Milestone Payments: Up to $50 million payable to Agenus, Exclusive License: Zydus gains exclusive rights in India and Sri Lanka.
Phase 3 Program
Agenus focuses on disciplined execution in 2026, advancing the Phase 3 program for BOT+BAL, expanding patient access, and progressing toward regulatory submission with substantial clinical datasets.
Manufacturing Capacity
Zydus acquires biologics manufacturing facilities in Emeryville and Berkeley, California, supporting BOT+BAL supply needs for clinical trials and future commercialization.
- The collaboration strengthens Agenus' balance sheet and secures dedicated U.S. manufacturing capacity.
- Agenus focuses on disciplined execution in 2026, advancing clinical programs and preparing for regulatory submission.
- Zydus gains exclusive rights in India and Sri Lanka, enhancing its global presence and potential revenue streams.
The collaboration with Zydus marks a significant step for Agenus in advancing its immunotherapy program and securing manufacturing capabilities for future growth.